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Summary
Background: Heart failure is a major public health problem in developed countries including
Japan, therefore it is important to estimate the future risk in patients with heart failure.
Recently, it has been reported that chronic kidney disease (CKD) is an independent predictor
for mortality in chronic heart failure. However, it is unknown whether CKD is an independent
predictor for mortality in acute heart failure. We retrospectively investigated the relationship
between estimated glomerular ﬁltration rate (eGFR) on admission for acute heart failure and
long-term mortality.
Methods: We analyzed 194 patients who were admitted for acute heart failure from Jan-
uary, 2002 to February, 2005. Patients were divided into two groups, high-eGFR group
(eGFR <60ml/min, n = 75) and low-eGFR group (eGFR ≥60ml/min, n = 119). eGFR was cal-
culated by equation of MDRD (modiﬁcation of the diet in renal disease) study. eGFR level
<60ml/min/1.73m2 is impaired renal function according to the guidelines of the Japanese
Society of Nephrology and of the National Kidney Foundation. Serum B-type natriuretic peptide
(BNP) level and left ventricular ejection fraction (LVEF), anemia, age, gender, and etiology of
heart failure were also evaluated. Median observation period was 609 days (range: 30—1627).
Mean age was 69 years and 138 patients were male.
Results: Median eGFR on admission was 74.2ml/min (range: 5.48—238.7), median BNP level was
840 pg/ml (range: 200—4800), and median LVEF was 36% (range: 11—81%). Forty-two percent
of patients had eGFR <60ml/min of eGFR at the time of coronary care unit admission. Patients
with low-eGFR had a signiﬁcantly lower mortality rate by Kaplan—Meier analysis (log rank test,
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p = 0.013). By Cox’s proportional-hazard analysis, eGFR was an independent factor for long-term
mortality of acute heart failure (p = 0.039).
Conclusions: Lower eGFR at the time of admission could be an independent predictor for mor-
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eart failure has become a major public health problem
n developed countries including Japan: therefore, it will
e very important to estimate the future risk in patients
ith heart failure. Several factors including older age, the
linical severity of the disease, low left ventricular ejec-
ion fraction, plasma B-type natriuretic peptide (BNP) level,
nd noradrenaline level have been established as indepen-
ent predictors for long-term prognosis of patients with
eart failure [1—7]. However, these factors were evaluated
n the stable phase of heart failure. There is a need for a
ew clinical marker measured at the time of the earlier
hase of acute heart failure to predict long-term progno-
is.
Chronic kidney disease (CKD) has been recognized as an
merging risk factor of future cardiovascular events in the
eneral population [8,9]. CKD could also affect the short-
erm as well as long-term prognosis in patients with a prior
istory of cardiovascular disease, including acute myocar-
ial infarction [10,11]. It has also been reported that CKD
s an independent risk factor for mortality and morbidity in
atients with chronic heart failure [1,12,13]. Glomerular ﬁl-
ration rate (GFR) is widely recognized as a useful marker
o evaluate renal function. CKD is deﬁned as a decrease
n glomerular ﬁltration rate (GFR) <60ml/min/1.73m2. The
urpose of this study is to investigate the relationship
etween GFR on long-term mortality among patients admit-
ed to a coronary care unit who recovered from acute heart
ailure.
ethods
e enrolled 194 consecutive patients who were admitted
o and discharged from the coronary care unit at Juntendo
niversity Hospital for the treatment of acute heart failure
rom January 1, 2002 to February 28, 2005. Patients with
ardiogenic shock as well as heart failure after major sur-
ical procedures were excluded. We also excluded patients
ho were receiving maintenance dialysis or who had already
eceived a kidney transplant. Patients were divided into two
roups according to the estimated GFR (eGFR) ≥60ml/min
r <60ml/min.
lood sampling and laboratory measurements
aseline blood sample was obtained on admission to the
oronary care unit. Serum creatinine and other labora-
ory data were measured by standard enzymatic methods.
lasma BNP measurements were performed by ﬂuorescence
nzyme immunoassay (FEIA) method. Echocardiography was
erformed on the day of admission to the coronary care unit.
eft ventricular ejection fraction (LVEF) was measured by
impson’s method.
H
l
P
tology. Published by Elsevier Ireland Ltd. All rights reserved.
stimation of renal function
GFR was calculated by the equation of the modiﬁca-
ion of the diet in renal disease (MDRD) study. eGFR
ml/min/1.73m2) = 186.3× [serum Cr]− 1.1154× [age]−
.176× [0.742 if patient is female] [14]. eGFR level
60ml/min/1.73m2 represents impaired renal function.
ollow-up data collection
e collected the patients’ clinical variables by chart
eview retrospectively. Follow-up date was obtained by out-
atients’ chart review if the current status of the patients
as clearly conﬁrmed. Follow-up data of the patents who
id not visit the out-patient clinic regularly were obtained
y telephone contact by the physicians.
tatistics
linical variables were compared between the subjects with
GFR 60ml/min (high-eGFR) and <60ml/min (low-eGFR).
tudent’s t-test of Fisher’s exact test was used for continu-
us variables analysis. 2 test was used for binary variables.
aplan—Meier survival curve was calculated for the evalua-
ion of long-term prognosis comparison with log rank test.
or the multiple variate analysis, Cox’s proportional-hazard
odel was used. A value of p < 0.05 was considered signiﬁ-
ant. Statistical analyses were performed with commercially
vailable statistics software (Stat View Version 5.0 ABACUS
oncepts for Windows, Berkeley, CA, USA).
esults
aseline patient characteristics of the study subjects are
hown in Table 1. We analyzed 194 patients; mean age was
9 years and 71% of the subjects were male. With regard to
he etiology of heart failure, 75 patients (39%) were ischemic
nd 119 patients (61%) were non-ischemic. Thirty-one per-
ent of the patients were diabetic. Median BNP level was
40 pg/ml (range: 200—4800), and median LVEF was 37%
range: 11—81). Median observational period was 609 days
range: 30—1627).
The distribution of eGFR is shown in Fig. 1. Median eGFR
as 74.2ml/min (range: 5.48—238.7). Forty-two percent of
atients suffered from renal dysfunction <60ml/min of eGFR
n CCU admission.emoglobin (Hb) level was signiﬁcantly lower in the
ow-eGFR group than the high-eGFR group (p < 0.0001).
lasma BNP was signiﬁcantly higher in the low-eGFR group
han the high-eGFR group (p < 0.0001). Prevalence of
eGFR in heart failure patients
Table 1 Baseline patient characteristics of the study
subjects.
n 194
Age (years) 69± 13
Gender (male/female) (%) 138/56 (71/29)
eGFR (ml/min) 74.2 (range: 5.48—238.7)
BNP (pg/ml) 840 (range: 200—4800)
LVEF (%) 36 (range: 11—81)
DM, n (%) 61 (31)
Etiology, n (%) Ischemic 75 (39),
non-ischemic 119 (61)
Median follow-up period (days) 609 (range: 30—1627)
BNP, B-type natruiretic peptide; DM, diabetes mellitus; LVEF,
left ventricular ejection fraction; eGFR, estimated glomerular
ﬁltration rate.
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tolic or diastolic cardiac function, ventricular hypertrophy
and remodeling, and adverse cardiovascular events [20].Figure 1 The distribution of estimated glomerular ﬁltration
rate (eGFR) at baseline.
diabetes mellitus was higher in the eGFR <60ml/min group
(p < 0.05). Mean age was signiﬁcantly higher in the low-eGFR
group than the high-eGFR group (p = 0.041). Gender, LVEF,
and etiology were not different between the two groups
(Table 2).
O
p
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Table 2 Comparison of baseline characteristics in terms of eGFR
Low-eGFR
n (%) 75 (39)
Age (years) 72± 11
Gender: male (%) 56 (72)
Hb (mg/dl) 10.9± 2
Cre (mg/dl) 2.17± 1.39
eGFR (ml/min) 37.80± 14
BNP (pg/ml) 1054 (210—4800)
LVEF (%) 38.7± 18
DM, n (%) 33 (43)
Etiology, n (%)
Ischemic 31(40)
Hb, hemoglobin; Cre, creatinine; BNP, B-type natriuretic peptide; LVEF
estimated glomerular ﬁltration rate.319
ong-term survival
wenty-one patients died from cardiovascular death; 7
atients in the high-eGFR group and 14 in the low-eGFR
roup, respectively. One patient died from malignancy
n the high-eGFR group. The patients with high-eGFR
howed signiﬁcantly lower mortality than the patients
ith low-eGFR (log rank test, p = 0.0128) (Fig. 2). Cox’s
roportional-hazards analysis indicated that eGFR was an
ndependent factor for long-term mortality of the study sub-
ects (p = 0.039) with the covariates including age, BNP, Hb,
VEF, diabetes, and etiology of heart failure (Table 3). How-
ver, there was no signiﬁcant difference between the high
nd low BNP groups if we divided the subjects by median
NP level (Fig. 3).
iscussion
he present study conﬁrmed that eGFR was an inde-
endent predictor of long-term mortality after discharge
mong patients with acute heart failure treated in the
oronary care unit. Recently, eGFR has been intensively
nvestigated as a cardiovascular risk factor in the general
opulation as well as patients who had already suffered
rom certain cardiovascular diseases [15]. These studies
onsistently demonstrated that eGFR was a signiﬁcant pre-
ictor for future events. In large-scale heart failure trials,
educed renal function was associated with signiﬁcantly
reater mortality and adverse cardiovascular event rates
16,17].
The mechanisms how renal function predict future
ardiovascular events could be multi-factorial and bidirec-
ional between cardiac and renal organ damage. Impaired
enal function could affect sodium handling, plasma vol-
me extension, blood pressure, and lipid metabolism. It
ould also induce oxidative stress and inﬂammation [18,19].
hronic kidney disease could contribute to impaired sys-n the other hand, acute and chronic failure of cardiac
erformance could cause progressive impairment of renal
unction. Worsening renal function in the context of heart
level.
High-eGFR p-Value
119 (61)
66± 14 0.041
82 (71) NS
12.7± 2.3 <0.0001
0.85± 0.20 <0.0001
94.85± 25 <0.0001
689 (200—2910) <0.0001
40.4± 19 NS
28 (23) 0.046
44 (38) NS
, left ventricular ejection fraction; DM, diabetes mellitus; eGFR,
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Figure 2 Kaplan—Meier mortality curves for high and
Table 3 Cox’s proportional-hazards analysis of risk factors
at baseline for overall mortality.
RR 95% CI p-Value
Age (>69 years) 2.711 1.158—6.356 0.022
eGFR (<60ml/min) 2.216 1.038—4.730 0.040
BNP (>840 pg/ml) 1.410 0.682—2.918 NS
Hb (<12mg/dl) 1.272 0.393—1.818 NS
LVEF (<40%) 1.096 0.513—2.339 NS
DM 0.897 0.386—2.086 NS
Ischemic 0.699 0.318—1.535 NS
RR, risk ratio; CI, conﬁdence interval; eGFR, estimated
glomerular ﬁltration rate; BNP, B-type natriuretic peptide; Hb,
hemoglobin; LVEF, left ventricular ejection fraction.
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Figure 3 Kaplan—Meier mortality curves for higlow estimated glomerular ﬁltration rate (eGFR).
ailure is associated with adverse clinical outcome and
onger hospitalization.
Furthermore, eGFR appears to have a greater predictive
alue than BNP in this population. Nonetheless impaired
enal function appears to be a sensitive marker of future
ardiovascular events and is a better predictor than BNP,
hich was already recognized as an established predictor in
atients with heart failure. Plasma levels of BNP could be
ltered by renal function and was thought to be less sensi-
ive as a predictor of future events in chronic renal failure
21]. The results of the present study were consistent with
his phenomenon which was reported in prior studies.
h and low B-type natriuretic peptide (BNP).
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2004;109:1004—9.eGFR in heart failure patients
Study limitations
The present study has several limitations. Because the
nature of the present study was retrospective analysis, cer-
tain confounding factors could not be avoided. We did not
collect the detailed treatment history which may also affect
the results. However, consistency with the prior studies
would support the importance of eGFR as a predictor of mor-
tality. Use of eGFR for risk estimation could have important
clinical implications.
Conclusion
Lower eGFR at the time of admission could be an indepen-
dent predictor for long-term mortality from heart failure.
Because heart failure is one of the most common diseases
in coronary care units in Japan, standard use of eGFR and
monitoring of renal function appears to be an important
and practical approach for the management of heart fail-
ure patients. Future studies should focus on the treatment
strategy for this emerging risk for the improvement of heart
failure management in the Japanese population.
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